Foamix commences dosing in Phase III trial for acne drug

Foamix Pharmaceuticals has commenced patient dosing in a Phase III clinical trial (FX2017-22) of its product candidate FMX101 in patients with moderate-to-severe acne.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news